The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

These changes lead to frequent inflammation and are not affected by drugs targeting the altered mucus production. Despite new medication, cystic fibrosis often leads to permanent lung damage.

BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...